Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (EXPAND)
Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice
Studieoversikt
Status
Status
Forhold
Forhold
Studietype
Studietype
Registrering (Forventet)
Registrering
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Koji Fukuda, M.D., Ph. D
- Telefonnummer: +81-22-717-7153
- E-post: fukuda@cardio.med.tohoku.ac.jp
Studiesteder
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-6574
- Rekruttering
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
-
Ta kontakt med:
- Koji Fukuda, MD, PhD
- Telefonnummer: +81-22-717-7153
- E-post: fukuda@cardio.med.tohoku.ac.jp
-
Hovedetterforsker:
- Hiroaki Shimokawa, MD, PhD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
Patients who meet all the criteria below
- Patients aged over 20 years
- Patients diagnosed with non-valvular atrial fibrillation
- Patients who are treated or will be treated with rivaroxaban
- Patients from whom written informed consent has been obtained
Exclusion Criteria:
Patients who meet any of the criteria below
- The following patients in whom rivaroxaban is contraindicated for use
- Patients with a history of allergies to the ingredients contained in this drug
- Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events)
- Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification)
- Patients having renal failure (creatinine clearance: <15 mL/min)
- Women who are or are likely to be pregnant
- Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir)
- Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
|---|
|
Non-valvular atrial fibrillation
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Combinations of symptomatic stroke (ischemic or hemorrhagic) and systemic embolism
Tidsramme: up to March/2016
|
Primary efficacy endpoint
|
up to March/2016
|
|
Clinically significant hemorrhagic events (massive hemorrhage in accordance with the ISTH classification)
Tidsramme: up to March/2016
|
Primary safety endpoint
|
up to March/2016
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Combinations of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction and cardiovascular death
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Symptomatic ischemic stroke
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Symptomatic hemorrhagic stroke
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Systemic embolism
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Acute myocardial infarction/unstable angina pectoris
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Cardiovascular death
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Deep vein thrombosis/pulmonary thromboembolism
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Transient ischemic attack
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Interventional/surgical treatment
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
All-cause death
Tidsramme: up to March/2016
|
Secondary efficacy endpoints
|
up to March/2016
|
|
Clinically insignificant hemorrhagic events (hemorrhagic events other than clinically significant hemorrhagic events)
Tidsramme: up to March/2016
|
Secondary safety endpoint
|
up to March/2016
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Forventet)
Primær fullføring
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- EXPAND study
- UMIN000009376 (Annen identifikator: UMIN)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .